Top Page
CSPC Pharmaceutical Group
(1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 29.54B | 31.47B | 31.59B | 27.41B | 23.58B |
| Gross Profit | 20.67B | 22.19B | 22.73B | 20.79B | 17.67B |
| EBITDA | 7.18B | 8.59B | 8.85B | 7.57B | 6.80B |
| Net Income | 4.41B | 5.88B | 6.22B | 5.51B | 4.88B |
Balance Sheet | |||||
| Total Assets | 47.23B | 50.92B | 41.77B | 42.50B | 35.65B |
| Cash, Cash Equivalents and Short-Term Investments | 8.25B | 13.09B | 13.87B | 13.87B | 10.47B |
| Total Debt | 507.33M | 706.90M | 659.28M | 115.04M | 375.51M |
| Total Liabilities | 11.20B | 11.26B | 11.07B | 9.37B | 7.96B |
| Stockholders Equity | 34.33B | 36.53B | 29.77B | 31.79B | 26.48B |
Cash Flow | |||||
| Free Cash Flow | 1.86B | 2.29B | 6.62B | 4.15B | 5.91B |
| Operating Cash Flow | 4.53B | 4.18B | 9.23B | 5.86B | 7.67B |
| Investing Cash Flow | -3.86B | 607.27M | -6.80B | -637.33M | -2.60B |
| Financing Cash Flow | -5.25B | -2.30B | -1.90B | -2.20B | -1.65B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $60.53B | 8.24 | 8.74% | 3.72% | -2.68% | -21.45% | |
72 Outperform | $141.38B | 31.20 | 9.79% | ― | 16.90% | 63.11% | |
66 Neutral | HK$216.05B | 41.10 | 16.09% | 0.99% | 8.68% | 0.82% | |
63 Neutral | $84.55B | 20.34 | 11.30% | 3.24% | -18.07% | -33.27% | |
55 Neutral | $148.82B | 116.92 | 8.41% | ― | 52.78% | ― | |
54 Neutral | $124.66B | 31.23 | 11.72% | 1.29% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Group has announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA drug, has received approval from China’s National Medical Products Administration for clinical trials. This drug, targeting complement component C5, is designed for treating IgA nephropathy and other complement-mediated diseases, offering long-lasting therapeutic effects and a promising clinical development value due to its superior pharmacological activity and safety profile.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its drug JSKN003 has received another Breakthrough Therapy Designation from China’s National Medical Products Administration for treating HER2-positive advanced colorectal cancer. This designation highlights the drug’s promising efficacy and safety profile, potentially enhancing the company’s position in the oncology market and addressing significant unmet clinical needs in cancer treatment.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 3,000,000 shares as part of its restricted share award scheme. This move, involving a total consideration of approximately HK$26,590,000, represents about 0.026% of the existing total number of shares in issue. The purchase is intended to benefit selected participants and reflects the company’s ongoing commitment to its share award scheme, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced the on-market purchase of 4,496,000 shares as part of its restricted share award scheme. This move, representing approximately 0.039% of the total shares in issue, is intended to benefit selected participants and reflects the company’s ongoing commitment to employee incentives and shareholder value.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 504,000 shares as part of its restricted share award scheme. This move, involving a total consideration of approximately HK$4,483,000, represents about 0.004% of the company’s existing shares and is intended to benefit selected participants, potentially enhancing stakeholder engagement and company performance.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 6,000,000 shares as part of its restricted share award scheme, representing approximately 0.052% of the total shares in issue. This strategic move is aimed at benefiting selected participants and reflects the company’s ongoing commitment to incentivize and retain talent, potentially strengthening its market position and shareholder value.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 3,000,000 shares as part of its restricted share award scheme, representing approximately 0.026% of the total shares in issue. This move is aimed at benefiting selected participants and reflects the company’s ongoing commitment to its share award scheme, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its new drug application for Efmedaglutide Alfa Injection, aimed at long-term weight management in overweight or obese adults, has been accepted by China’s National Medical Products Administration. This acceptance, based on successful Phase III clinical trials, highlights the drug’s efficacy in reducing body weight and improving cardiovascular and metabolic parameters, with a favorable safety profile. The company is also conducting further trials for type 2 diabetes, potentially expanding its impact on patient care.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its Tacrolimus Extended-release Capsules have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the area of immunological rejection, potentially strengthening its market position and offering new treatment options for graft rejection in kidney and liver transplant patients.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has received approval from the U.S. FDA to conduct clinical trials for its new siRNA drug, SYH2070 Injection, in the United States. This drug, designed for liver-targeted delivery, shows promise in treating hypertriglyceridemia or mixed hyperlipidemia by effectively reducing ANGPTL3 levels. Preclinical studies indicate that SYH2070 offers superior pharmacological activity and a long-lasting therapeutic effect, positioning it as a potential leader in its category with significant clinical development value.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced the proposed listing of its subsidiary, CSPC Innovation, on the Main Board of the Stock Exchange. This move is expected to reduce CSPC’s equity interest in CSPC Innovation by approximately 8.46%, constituting a discloseable transaction under the Listing Rules. The listing is subject to market conditions and regulatory approvals, and if successful, will involve an initial public offering of new H Shares, representing up to 10% of CSPC Innovation’s enlarged share capital. The announcement highlights CSPC’s strategic efforts to enhance its market presence and operational growth through this listing.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced that its new drug, SYH2070 Injection, has received approval from China’s National Medical Products Administration for clinical trials. This siRNA drug, designed for liver-targeted delivery to reduce ANGPTL3 levels, shows promise in treating hypertriglyceridemia and mixed hyperlipidemia, with preclinical studies highlighting its superior pharmacological activity and long-lasting effects compared to similar products, potentially enhancing the company’s position in the pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its Lecanemab Injection has received approval from China’s National Medical Products Administration to conduct clinical trials. This marks the first biosimilar to lecanemab injection approved for clinical trials in China, aimed at treating mild cognitive impairment and mild Alzheimer’s disease dementia. The approval signifies a significant step in CSPC’s efforts to expand its market presence in the Alzheimer’s treatment sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the grant of 9,000,000 restricted shares to an employee under its share award scheme. This initiative is designed to recognize the employee’s contributions and incentivize future performance in line with the company’s strategic goals. The shares will vest in four tranches from 2026 to 2029, contingent upon the achievement of specific performance targets. This move aims to retain talent and align employee interests with the company’s growth objectives.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its subsidiary, AlaMab Therapeutics Inc., has received approval to conduct a Phase II clinical trial in China for ALMB-0166, a novel treatment for Parkinson’s disease. This first-in-class humanized monoclonal antibody inhibitor targets the Connexin 43 protein to provide neuroprotection by inhibiting neuroinflammatory mediators. The approval marks a significant step in addressing the urgent need for innovative treatments in Parkinson’s disease, potentially improving patient outcomes and positioning CSPC as a leader in neurological disorder therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its innovative SYH2066 Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This novel oral small molecule drug targets the respiratory syncytial virus (RSV) and is expected to become a significant therapeutic option, as there are currently no approved small molecule drugs for RSV globally. The approval marks a promising step in the company’s clinical development, potentially enhancing its industry position and offering new treatment possibilities for respiratory infections caused by RSV.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its new drug application for KN026 (Anbenitamab Injection), co-developed with Jiangsu Alphamab Oncology, has been accepted by China’s National Medical Products Administration. This drug, an anti-HER2 bispecific antibody, is intended for the treatment of HER2-positive gastric cancer and has shown promising results in clinical trials, including improved survival rates and safety profiles. The acceptance marks a significant advancement in CSPC’s efforts to provide effective second-line treatments for gastric cancer, with ongoing trials for other solid tumors.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited is a Hong Kong-based comprehensive pharmaceutical enterprise focusing on research, development, manufacturing, and sales of innovative drugs across key therapeutic areas such as oncology, psychiatry, and cardiovascular diseases. The company is known for its strong emphasis on innovation and internationalization, with a robust R&D team and multiple international collaborations.
CSPC Pharmaceutical Group announced that its SYS6036 Injection, a humanized monoclonal antibody drug for cancer immunotherapy, has received approval from China’s National Medical Products Administration to begin clinical trials. This approval marks a significant step for the company in advancing its cancer treatment offerings, potentially enhancing its market position in the oncology sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group reported a significant decline in its financial performance for the first half of 2025, with total revenue decreasing by 18.5% and profit attributable to shareholders dropping by 15.6% compared to the previous year. The company declared a reduced interim dividend and continued its share buy-back program to enhance shareholder returns. Despite the financial setbacks, CSPC remains committed to its strategic focus on innovation and internationalization, aiming to strengthen its market position and drive sustainable development.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced an interim dividend of HKD 0.14 per share for the six months ending June 30, 2025. This decision reflects the company’s ongoing commitment to delivering shareholder value and may enhance its attractiveness to investors, potentially strengthening its market position.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar targeting IL-4Rα for treating moderate-to-severe atopic dermatitis in adults, has received approval from China’s National Medical Products Administration for clinical trials. This approval marks a significant step in the company’s efforts to expand its biosimilar portfolio and strengthen its position in the Chinese pharmaceutical market, potentially impacting stakeholders positively by enhancing treatment options and driving growth.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, reported its unaudited financial results for the first half of 2025, revealing a 7.99% increase in operating revenue compared to the same period last year. However, the company experienced a net loss attributable to shareholders, highlighting challenges in profitability despite increased revenue. The announcement underscores the importance for stakeholders to exercise caution when dealing in the company’s securities due to the unaudited nature of the financial information.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for August 22, 2025, to approve the unaudited interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market position.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its application for marketing approval of Semaglutide Injection, a treatment for type 2 diabetes, has been accepted by China’s National Medical Products Administration. This product, developed by its subsidiary CSPC Baike, shows significant clinical advantages in glycemic control and safety compared to existing treatments. The company is also conducting trials for its use in treating obesity, indicating a strategic expansion in its product offerings to benefit a broader patient base.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has entered into an exclusive license agreement with Madrigal Pharmaceuticals for the global development, manufacturing, and commercialization of its oral small molecule GLP-1 receptor agonist, SYH2086. Under this agreement, CSPC will receive up to $2.075 billion, including an upfront payment and potential milestone payments, while retaining rights to develop similar products in China. This strategic partnership is expected to enhance CSPC’s market positioning in the pharmaceutical industry, particularly in the diabetes and obesity treatment sectors.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.